返回 Agenda
Session 6: Growing Clinical Use and Experience: What Can be Learned From Key International Initiatives?
Session Chair(s)
Julie Marechal-Jamil, MSc
Director, Biosimilar Policy and Science
Medicines For Europe, Belgium
Jian Wang, MD, PhD
Division Manager, Clinical Review Division – Heamatology/Oncology
Health Canada, Canada
Biosimilar medicines have been available globally for nearly 14 years. As they entered various regions and countries, policy makers, healthcare community stakeholders have devised different ways to introduce these medicines in the medical practice, grow the use of biosimilar medicines and enhance care for patients. The experience and confidence in biosimilar medicines keeps expanding, yet at different pace and rate depending on geographies. In this session, 3 initiatives (from outside the U.S.) supporting biosimilar uptake and clinical use will be presented followed by a discussion on the learnings, including key principles and key enablers.
Learning Objective : At the conclusion of this session, participants should be able to:
- Share concrete examples of conducive biosimilar policy measures
- Inspire creative approaches to deliver broad healthcare benefits from biosimilar use
- Emulate experience sharing as driver towards policy implementation
Speaker(s)
The pan-Canadian Oncology Biosimilar Initiative: Building Confidence Through Engagement and Education
Scott Gavura, MBA, RPh
Ontario Health (Cancer Care Ontario), Canada
Director of Provincial Drug Reimbursement Programs
UK Lessons Learned from Multi-Winner Tenders
Blake Dark
NHS, England, United Kingdom
Commercial Medicines Director
France National Health Strategy and Biosimilar Pilot Sharing Scheme
Etienne Nedellec, PharmD, MSc
Ministry of Social Affairs and Health, France
French National Health Care Directorate